<DOC>
	<DOCNO>NCT02540369</DOCNO>
	<brief_summary>To describe use intravitreal aflibercept routine clinical practice describe follow-up well treatment pattern patient wAMD DME routine clinical practice Canada study population treatment naive patient receive prior therapy ( anti-VEGF injection , laser , steroid , etc ) .</brief_summary>
	<brief_title>To Describe Use Intravitreal Aflibercept Describe Follow-up Well Treatment Patterns Patients With Wet Age-related Macular Degeneration ( wAMD ) Diabetic Macular Edema ( DME ) Routine Clinical Practice Canada .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Age : &gt; = 18 year age Male female Patients wet AMD ( wet agerelated macular degeneration ) Diabetic macular edema ( DME ) treat intravitreal aflibercept accord Canadian Product monograph recommendation routine clinical practice . Decision treat intravitreal aflibercept prior patient enrolment per physician 's routine clinical practice . Patients participate investigational program intervention outside routine clinical practice . Patients currently treat intravitreal aflibercept . This study include patient new intravitreal aflibercept , na√Øve previously treat antiVEGF therapy . Patients hypersensitive drug , ingredient formulation , component container . Patients hypersensitive drug , ingredient formulation , component container . Ocular periocular infection Active intraocular inflammation Scar , fibrosis , atrophy involve center fovea study eye . Any concomitant therapy another agent treat wet AMD DME study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Wet Age-related macular degeneration</keyword>
</DOC>